Vesneo: Phase III data

Top-line data from the double-blind, international Phase III APOLLO and LUNAR trials in a total of 840 patients with open-angle glaucoma or ocular hypertension showed that once-daily Vesneo met the primary endpoint in both trials of non-inferiority to twice-daily timolol in reducing mean IOP at specified time points during 3 months of treatment. Vesneo also significantly reduced mean IOP by 7.5-9.1 mmHg from baseline between weeks 2 and 12 vs. timolol in both trials (p<0.05 for both). Vesneo was well tolerated. ...